Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
From Exemplary to Current: Famous Rings Available - 2Incredible Travel Objections for Craftsmanship Darlings to Visit
- 3Winona Ryder didn't take the 'Stranger Things' plot lightly. How 'otherworldly' grief and a kidnapping in her hometown informed her character.
- 4Don’t let food poisoning crash your Thanksgiving dinner
- 5I spent the last year transforming my life. Becoming a Rockette for a day made me confront a fear I couldn't shake.
- African Forests Have Become a Source of Carbon Emissions
- The Best Music Collections of the 10 years
- IDF finds weapon of slain hostage Capt. Daniel Perez in booby-trapped Gaza compound
- Simple Consideration Plants for Home and Office: An Aide
- As infant botulism cases climb to 31, recalled ByHeart baby formula is still on some store shelves
- New Cheetos and Doritos will be free of artificial dyes
- Marvel's X-Men are joining the battle in 'Avengers: Doomsday': Watch the teaser
- Find Wonderful Stream Voyage Objections On the planet
- Former 'Bachelorette' welcomes 1st baby via emergency c-section
